{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:35Z","timestamp":1787162615010,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,6]]},"DOI":"10.7759\/cureus.80172","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:12:57Z","timestamp":1741288377000},"source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of Immunosuppressive Therapy in Preventing the Progression of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Scott","family":"Nall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaria","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulazizi","family":"Ahmed Mohsen Alrashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alhneif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hannan Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Mubarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Ahmed Mohsen Alrashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Allahwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S389629","article-title":"Ocular myasthenia gravis: a current overview","volume":"15","author":"Behbehani R","year":"2023","unstructured":"Behbehani R. Ocular myasthenia gravis: a current overview. Eye Brain. 2023, 15:1-13. 10.2147\/EB.S389629","journal-title":"Eye Brain"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2022.2029683","article-title":"Ocular myasthenia gravis: a review and practical guide for clinicians","volume":"105","author":"Shuey NH","year":"2022","unstructured":"Shuey NH. Ocular myasthenia gravis: a review and practical guide for clinicians. Clin Exp Optom. 2022, 105:205-13. 10.1080\/08164622.2022.2029683","journal-title":"Clin Exp Optom"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231163819","article-title":"Immunotherapy for ocular myasthenia gravis: an observational study in Japan","volume":"16","author":"Narita T","year":"2023","unstructured":"Narita T, Nakane S, Nagaishi A, et al.. Immunotherapy for ocular myasthenia gravis: an observational study in Japan. Ther Adv Neurol Disord. 2023, 16:17562864231163819. 10.1177\/17562864231163819","journal-title":"Ther Adv Neurol Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-024-02552-7","article-title":"Recommendations for the management of myasthenia gravis in Belgium","volume":"124","author":"De Bleecker JL","year":"2024","unstructured":"De Bleecker JL, Remiche G, Alonso-Jim\u00e9nez A, Van Parys V, Bissay V, Delstanche S, Claeys KG. Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol Belg. 2024, 124:1371-83. 10.1007\/s13760-024-02552-7","journal-title":"Acta Neurol Belg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00292-x","article-title":"Risk factors for generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study","volume":"11","author":"Guo RJ","year":"2022","unstructured":"Guo RJ, Gao T, Ruan Z, et al.. Risk factors for generalization in patients with ocular myasthenia gravis: a multicenter retrospective cohort study. Neurol Ther. 2022, 11:73-86. 10.1007\/s40120-021-00292-x","journal-title":"Neurol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren J","year":"2020","unstructured":"Morren J, Li Y. Maintenance immunosuppression in myasthenia gravis, an update. J Neurol Sci. 2020, 410:116648. 10.1016\/j.jns.2019.116648","journal-title":"J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.04.006","article-title":"Myasthenia gravis. Update on diagnosis and therapy","volume":"161","author":"Garc\u00eda Est\u00e9vez DA","year":"2023","unstructured":"Garc\u00eda Est\u00e9vez DA, Pardo Fern\u00e1ndez J. Myasthenia gravis. Update on diagnosis and therapy. Med Clin (Barc). 2023, 161:119-27. 10.1016\/j.medcli.2023.04.006","journal-title":"Med Clin (Barc)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/CON.0000000000001161","article-title":"Diagnosis and management of myasthenia gravis","volume":"28","author":"Hehir MK 2nd","year":"2022","unstructured":"Hehir MK 2nd, Li Y. Diagnosis and management of myasthenia gravis. Continuum (Minneap Minn). 2022, 28:1615-42. 10.1212\/CON.0000000000001161","journal-title":"Continuum (Minneap Minn)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2017.1344237","article-title":"Factors affecting outcome in ocular myasthenia gravis","volume":"128","author":"Mazzoli M","year":"2018","unstructured":"Mazzoli M, Ariatti A, Valzania F, Kaleci S, Tondelli M, Nichelli PF, Galassi G. Factors affecting outcome in ocular myasthenia gravis. Int J Neurosci. 2018, 128:15-24. 10.1080\/00207454.2017.1344237","journal-title":"Int J Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12932\/AP-260521-1141","article-title":"Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: a 5-year analysis","author":"Kemchoknatee P","year":"2021","unstructured":"Kemchoknatee P, Arepagorn A, Srisombut T. Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: a 5-year analysis. Asian Pac J Allergy Immunol. 2021, 10.12932\/AP-260521-1141","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21555","article-title":"Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis","volume":"41","author":"Allen JA","year":"2010","unstructured":"Allen JA, Scala S, Jones HR. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis. Muscle Nerve. 2010, 41:379-84. 10.1002\/mus.21555","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327669.75695.38","article-title":"Treatment of ocular symptoms in myasthenia gravis","volume":"71","author":"Bhanushali MJ","year":"2008","unstructured":"Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology. 2008, 71:1335-41. 10.1212\/01.wnl.0000327669.75695.38","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 years in patients with ocular myasthenia gravis","volume":"60","author":"Kupersmith MJ","year":"2003","unstructured":"Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol. 2003, 60:243-8. 10.1001\/archneur.60.2.243","journal-title":"Arch Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith MJ","year":"2009","unstructured":"Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009, 256:1314-20. 10.1007\/s00415-009-5120-8","journal-title":"J Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis","volume":"23","author":"Mee J","year":"2003","unstructured":"Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003, 23:251-5. 10.1097\/00041327-200312000-00002","journal-title":"J Neuroophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209722","article-title":"Effect of immunosuppression in risk of developing generalized symptoms in ocular myasthenia gravis: a retrospective cohort study","volume":"103","author":"Menon D","year":"2024","unstructured":"Menon D, Alharbi M, Katzberg HD, Bril V, Mendoza MG, Barnett-Tapia C. Effect of immunosuppression in risk of developing generalized symptoms in ocular myasthenia gravis: a retrospective cohort study. Neurology. 2024, 103:e209722. 10.1212\/WNL.0000000000209722","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul NT","year":"2004","unstructured":"Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004, 217:131-3. 10.1016\/j.jns.2003.08.017","journal-title":"J Neurol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.010","article-title":"Prognosis of ocular myasthenia gravis: retrospective multicenter analysis","volume":"122","author":"Nagia L","year":"2015","unstructured":"Nagia L, Lemos J, Abusamra K, Cornblath WT, Eggenberger ER. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology. 2015, 122:1517-21. 10.1016\/j.ophtha.2015.03.010","journal-title":"Ophthalmology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15292","article-title":"Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a\u00a0propensity score analysis","volume":"29","author":"Ruan Z","year":"2022","unstructured":"Ruan Z, Guo R, Zhou H, et al.. Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a\u00a0propensity score analysis. Eur J Neurol. 2022, 29:1805-14. 10.1111\/ene.15292","journal-title":"Eur J Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12057","article-title":"The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis","volume":"20","author":"Zach H","year":"2013","unstructured":"Zach H, Cetin H, Hilger E, et al.. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur J Neurol. 2013, 20:708-13. 10.1111\/ene.12057","journal-title":"Eur J Neurol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419876521","article-title":"Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis","volume":"12","author":"Li M","year":"2019","unstructured":"Li M, Ge F, Guo R, et al.. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2019, 12:1756286419876521. 10.1177\/1756286419876521","journal-title":"Ther Adv Neurol Disord"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny I","year":"2019","unstructured":"Koneczny I, Herbst R. Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019, 8:671. 10.3390\/cells8070671","journal-title":"Cells"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser L","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021, 10:2235. 10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial","volume":"53","author":"Benatar M","year":"2016","unstructured":"Benatar M, Mcdermott MP, Sanders DB, et al.. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): a randomized, controlled trial. Muscle Nerve. 2016, 53:363-9. 10.1002\/mus.24769","journal-title":"Muscle Nerve"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli A","year":"1988","unstructured":"Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand. 1988, 77:31-5. 10.1111\/j.1600-0404.1988.tb06970.x","journal-title":"Acta Neurol Scand"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7638-2","article-title":"Long-term outcome of 424 childhood-onset myasthenia gravis patients","volume":"262","author":"Gui M","year":"2015","unstructured":"Gui M, Luo X, Lin J, et al.. Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol. 2015, 262:823-30. 10.1007\/s00415-015-7638-2","journal-title":"J Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/343981-effectiveness-of-immunosuppressive-therapy-in-preventing-the-progression-of-ocular-myasthenia-gravis-to-generalized-myasthenia-gravis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:13:00Z","timestamp":1741288380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/343981-effectiveness-of-immunosuppressive-therapy-in-preventing-the-progression-of-ocular-myasthenia-gravis-to-generalized-myasthenia-gravis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.80172","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}